Literature DB >> 20089113

Lymph node dissection during robotic-assisted laparoscopic prostatectomy: comparison of lymph node yield and clinical outcomes when including common iliac nodes with standard template dissection.

Darren J Katz1, David S Yee, Guilherme Godoy, Lucas Nogueira, Kian Tai Chong, Jonathan A Coleman.   

Abstract

OBJECTIVE: To compare the perioperative outcomes of standard pelvic to full-template lymph node (LN) dissection (LND) during robotic-assisted laparoscopic prostatectomy (RALP). PATIENTS AND METHODS: The study included 94 patients undergoing RALP with LND between January 2007 and August 2008, by one surgeon. In February 2008 the LND template was modified to include common iliac and medial hypogastric LNs. Clinical and pathological patient characteristics were analysed, including total number of retrieved and positive LNs in each area of dissection, operative duration and complications.
RESULTS: Of the 94 patients, 62 underwent standard LND (group 1) and 32 underwent full-template pelvic LND (group 2). The median (mean) number of LNs retrieved in groups 1 and 2 were 12 (13.3) and 17.5 (21.4), respectively. Of the five patients with positive LNs (5%), four were in group 2 (13%); two of these patients had positive LNs in the common iliac dissection, and for one of these patients it was the sole site of involvement. Deep venous thrombosis, pulmonary embolism or transient neuropraxia occurred in six patients (five in group 1 and one in group 2). The median additional operative time for resection of common and internal LNs was 25 min.
CONCLUSIONS: LN yield increased and additional sites of LN metastases were identified during full-template pelvic LND during RALP. This modification was not associated with an increased rate of complications. Derived benefits of including additional nodal dissection and the effect on staging accuracy remain to be determined.

Entities:  

Mesh:

Year:  2010        PMID: 20089113     DOI: 10.1111/j.1464-410X.2009.09102.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  7 in total

1.  Prostate cancer: risk versus benefit of lymph node dissection during prostatectomy.

Authors:  Christopher J Kane; Michael A Liss
Journal:  Nat Rev Urol       Date:  2013-04-23       Impact factor: 14.432

Review 2.  How to minimize lymphoceles and treat clinically symptomatic lymphoceles after radical prostatectomy.

Authors:  Hak J Lee; Christopher J Kane
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

3.  Comparison of the diagnostic efficacy and perioperative outcomes of limited versus extended pelvic lymphadenectomy during robot-assisted radical prostatectomy: a multi-institutional retrospective study in Japan.

Authors:  Shuichi Morizane; Masashi Honda; Satoshi Fukasawa; Atsushi Komaru; Junichi Inokuchi; Masatoshi Eto; Masaki Shimbo; Kazunori Hattori; Yoshiaki Kawano; Atsushi Takenaka
Journal:  Int J Clin Oncol       Date:  2017-12-11       Impact factor: 3.402

4.  Extended pelvic lymph node dissection at the time of robot-assisted radical prostatectomy: Impact of surgical volume on efficacy and complications in a single-surgeon series.

Authors:  Giovanni Battista Di Pierro; Pietro Grande; Johann Gregory Wirth; Hansjörg Danuser; Agostino Mattei
Journal:  Can Urol Assoc J       Date:  2015 Mar-Apr       Impact factor: 1.862

Review 5.  Complications of pelvic lymph node dissection for prostate cancer.

Authors:  K A Keegan; M S Cookson
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

Review 6.  Current technique and results for extended pelvic lymph node dissection during robot-assisted radical prostatectomy.

Authors:  Roger Li; Firas G Petros; Janet B Kukreja; Stephen B Williams; John W Davis
Journal:  Investig Clin Urol       Date:  2016-12-08

7.  Laparoscopic radical prostatectomy and extended pelvic lymph node dissection: a combined technique.

Authors:  Piotr Jarzemski; Sławomir Listopadzki; Piotr Słupski; Marcin Jarzemski; Bartosz Brzoszczyk; Roman Sosnowski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2020-02-02       Impact factor: 1.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.